Research programme: monoclonal antibodies - Viragen/Roslin Institute

Drug Profile

Research programme: monoclonal antibodies - Viragen/Roslin Institute

Latest Information Update: 04 Feb 2008

Price : $50

At a glance

  • Originator Roslin Institute; Viragen
  • Developer Viragen
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 25 Jun 2007 Viragen has halted development of the OVA™ System and intends to terminate its research and license agreements with Roslin Institute and Oxford BioMedica
  • 14 Oct 2004 Viragen has acquired an exclusive worldwide licence to Oxford BioMedica's LentiVector® gene delivery technology to develop Avian Transgenic Technology in its collaboration with Roslin Institute
  • 19 May 2003 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top